235 related articles for article (PubMed ID: 37298389)
21. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
22. Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer.
Song SY; Park JH; Park SJ; Kang IC; Yoo HS
Integr Cancer Ther; 2022; 21():15347354221144311. PubMed ID: 36565160
[TBL] [Abstract][Full Text] [Related]
23. Cyclophilin A/CD147 Interaction: A Promising Target for Anticancer Therapy.
Han JM; Jung HJ
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012604
[TBL] [Abstract][Full Text] [Related]
24. PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.
Mittal S; Kamath A; Joseph AM; Rajala MS
Int J Oncol; 2020 Oct; 57(4):989-1000. PubMed ID: 32945365
[TBL] [Abstract][Full Text] [Related]
25. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.
Cheng CC; Chou KF; Wu CW; Su NW; Peng CL; Su YW; Chang J; Ho AS; Lin HC; Chen CG; Yang BL; Chang YC; Chiang YW; Lim KH; Chang YF
Lung Cancer; 2018 Feb; 116():80-89. PubMed ID: 29413056
[TBL] [Abstract][Full Text] [Related]
26. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
Jia Z; Zhang Y; Yan A; Wang M; Han Q; Wang K; Wang J; Qiao C; Pan Z; Chen C; Hu D; Ding X
Cell Death Dis; 2020 Aug; 11(8):670. PubMed ID: 32820157
[TBL] [Abstract][Full Text] [Related]
27. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Hirsh V
BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
[TBL] [Abstract][Full Text] [Related]
28. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
[TBL] [Abstract][Full Text] [Related]
29. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
30. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
31. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Tamura T; Kawakado K; Makimoto G; Nakanishi M; Kuyama S
Thorac Cancer; 2021 Jun; 12(11):1770-1774. PubMed ID: 33942527
[TBL] [Abstract][Full Text] [Related]
32. CD147-mediated glucose metabolic regulation contributes to the predictive role of
Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
[TBL] [Abstract][Full Text] [Related]
33. A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.
Lee HJ; Min HY; Yong YS; Ann J; Nguyen CT; La MT; Hyun SY; Le HT; Kim H; Kwon H; Nam G; Park HJ; Lee J; Lee HY
Theranostics; 2022; 12(1):105-125. PubMed ID: 34987637
[No Abstract] [Full Text] [Related]
34. FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC.
Cao S; Wang Z; Gao X; He W; Cai Y; Chen H; Xu R
J Exp Clin Cancer Res; 2018 Sep; 37(1):220. PubMed ID: 30189871
[TBL] [Abstract][Full Text] [Related]
35. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
36. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
[TBL] [Abstract][Full Text] [Related]
37. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
[TBL] [Abstract][Full Text] [Related]
38. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
39. Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.
Takahashi A; Seike M; Chiba M; Takahashi S; Nakamichi S; Matsumoto M; Takeuchi S; Minegishi Y; Noro R; Kunugi S; Kubota K; Gemma A
Sci Rep; 2018 Oct; 8(1):14896. PubMed ID: 30291293
[TBL] [Abstract][Full Text] [Related]
40. CD147-Cyclophilin a Interactions Promote Proliferation and Survival of Cutaneous T-Cell Lymphoma.
Sakamoto M; Miyagaki T; Kamijo H; Oka T; Boki H; Takahashi-Shishido N; Suga H; Sugaya M; Sato S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]